Adocia is a clinical-stage biotechnology company based in Lyon, France, founded in 2005 and initially named Proteins & Peptides Management S.A.S. It focuses on the development of innovative formulations of approved therapeutic proteins and peptides to treat diabetes and other metabolic diseases. The company utilizes its proprietary Biochaperone technology platform, which enhances the efficacy of these therapeutic agents. Adocia's clinical pipeline features products like Biochaperone Lispro, Biochaperone Combo, and Biochaperone Glucagon, while its pre-clinical pipeline includes BioChaperone LisPram and BioChaperone Glargine GLP-1, among others. Additionally, the company holds a patent portfolio that encompasses chronic wound healing, insulin therapy, and monoclonal antibodies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.